The Quantellect read.As of Nov 19, 2026, 11 active firms cover Twist Bioscience Corp: 7 rate it Buy or better, 3 sit at Neutral, and 1 rate it Sell or worse, a buy consensus. The target range is very wide, $45.00 to $215.00 (about 4.8x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $153.00 sits 31% above the current $116.39. Sentiment has cooled somewhat, with Sell ratings rising from 0 to 1 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.12 next quarter toward $0.07 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS11 active firms
Buy
Strong Buy00%
Buy764%
Neutral327%
Sell19%
Strong Sell00%
Based on 11 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$153.00
+31.5% upside
Average target across 11 active firms as of Nov 19, 2026 vs $116.39 current
Highest Target$215.00
Average Target$153.00
Lowest Target$45.00
Detailed analyst forecasts for TWST
Showing 1–11 of 11 named analysts shown · 11 active firms in the rating projection
As of Nov 19, 2026, 7 of 11 active firms rate TWST a Buy (3 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
TWST EPS & revenue forecast
EPS · NEXT QUARTER
$-0.12
Range $-0.29 – $-0.02 · 3 analysts · -80% YoY
Next period, 3 analysts expect Twist Bioscience Corp to earn $-0.12 a share (range $-0.29 – $-0.02), versus $-0.60 a year earlier. Full-year consensus is $-0.52, growing to $0.07 the year after.
REVENUE · NEXT QUARTER
$134.8M
Range $130.9M – $136.7M · 3 analysts · +22% YoY
Revenue is expected to reach $134.8M (range $130.9M – $136.7M), +21.7% year-over-year. Full-year consensus is $556.0M, rising to $660.3M next year.
Top analysts covering Twist Bioscience Corp
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TWST.
#1
Hamed Khorsand
BWS Financial · Rank #23
Sell
$45.00-61.3% to target
Overall win rate
51%
+ Follow
#2
Puneet Souda
Leerink Partners · Rank #30
Buy
$190.00+63.2% to target
Overall win rate
57%
+ Follow
#3
SJ
Sung Ji Nam
Scotiabank · Rank #186
Buy
$62.00-46.7% to target
Overall win rate
47%
+ Follow
#4
KM
Kyle Mikson
Canaccord Genuity · Rank #202
Buy
$205.00+76.1% to target
Overall win rate
40%
+ Follow
#5
Luke Sergott
Barclays · Rank #267
Buy
$215.00+84.7% to target
Overall win rate
43%
+ Follow
TWST stock forecast FAQ
What is TWST's average 12-month price target?+
The 11 active firms with a live target average $153.00 for Twist Bioscience Corp over the next 12 months, ranging from a $215.00 high to a $45.00 low, as of Nov 19, 2026.
Is TWST stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 11 active firms as of Nov 19, 2026, 7 rate it Buy or Strong Buy, 3 rate it Neutral, and 1 rate it Sell or Strong Sell.
What are the highest and lowest price targets for TWST?+
The Street-high target is $215.00 (Barclays), and the Street-low is $45.00 (BWS Financial). The average of all 11 active-firm targets is $153.00.
How many active Wall Street firms cover TWST?+
11 active firms have a recognized rating on Twist Bioscience Corp as of Nov 19, 2026, and 11 active firms carry a live 12-month price target.
Who is the most accurate analyst covering TWST?+
Among analysts who currently cover TWST, Hamed Khorsand of BWS Financial has the strongest overall Quantellect track record (Rank #23). Their current call is Sell with a $45.00 target.
What is Twist Bioscience Corp's projected EPS for next quarter?+
The consensus estimate is $-0.12 per share (range $-0.29 – $-0.02) across 3 analysts. Full-year EPS is projected at $-0.52, rising to $0.07 the following year.
How much revenue is Twist Bioscience Corp expected to report next quarter?+
Consensus revenue is $134.8M (range $130.9M – $136.7M). Full-year revenue is projected at $556.0M, growing to $660.3M next year.
Have analysts been upgrading or downgrading TWST lately?+
As of Nov 19, 2026, 7 of 11 active firms rate TWST a Buy (3 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TWST calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.